Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Congenital Abnormalities 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Acute 8Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Multiple Myeloma 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, Mantle-Cell 6Leukemia 6Sezary Syndrome 5Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma 5Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Blast Crisis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Leukemia, Myeloid, Chronic-Phase 3

Interventions

Gemcitabine 43pembrolizumab 36Paclitaxel 36Nivolumab 31Docetaxel 29Capecitabine 29Bevacizumab 29Oxaliplatin 28Fluorouracil 28Cisplatin 26Leucovorin 24Cyclophosphamide 23Radiosurgery 20Irinotecan 20Carboplatin 20aldesleukin 19Cetuximab 19Interleukin-2 16fludarabine phosphate 15fludarabine 15Pemetrexed 15Trastuzumab 14Magnetic Resonance Spectroscopy 14Ipilimumab 14Fulvestrant 14130-nm albumin-bound paclitaxel 14Prednisone 13Everolimus 13Radiotherapy 12Panitumumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm Metastasis × Flow Cytometry × Clear all
NCT00514215 2020-03-05

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
8 enrolled 5 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡